Promising treatments of tomorrow for multiple sclerosis

Daniel M. Harrison, Peter Calabresi

Research output: Contribution to journalArticle

Abstract

The therapeutic options for multiple sclerosis are rapidly expanding. What was once seen as a disease with little hope for treatment is now a target of rapid drug development. Current therapies have demonstrated efficacy in limiting the impact of the disease, but none is fully effective in all patients. However, promising new treatments are on the horizon. In this review we will discuss potential novel immunomodulating drugs that are in advanced stages of investigation; these drugs include monoclonal antibodies, chimeric molecules, and oral therapies. The use of hematopoietic stem cells will also be discussed and, in addition, we will look farther ahead at possible novel targets for the development of new immunomodulatory or neuroprotective pharmaceuticals.

Original languageEnglish (US)
Pages (from-to)283-290
Number of pages8
JournalAnnals of Indian Academy of Neurology
Volume12
Issue number4
DOIs
StatePublished - Oct 1 2009

Fingerprint

Multiple Sclerosis
Pharmaceutical Preparations
Therapeutics
Neuroprotective Agents
Cerebral Palsy
Hematopoietic Stem Cells
Monoclonal Antibodies

Keywords

  • Drugs
  • Investigational
  • Multiple sclerosis
  • Therapeutics

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Promising treatments of tomorrow for multiple sclerosis. / Harrison, Daniel M.; Calabresi, Peter.

In: Annals of Indian Academy of Neurology, Vol. 12, No. 4, 01.10.2009, p. 283-290.

Research output: Contribution to journalArticle

@article{11a8777960764be78246fef975ed625a,
title = "Promising treatments of tomorrow for multiple sclerosis",
abstract = "The therapeutic options for multiple sclerosis are rapidly expanding. What was once seen as a disease with little hope for treatment is now a target of rapid drug development. Current therapies have demonstrated efficacy in limiting the impact of the disease, but none is fully effective in all patients. However, promising new treatments are on the horizon. In this review we will discuss potential novel immunomodulating drugs that are in advanced stages of investigation; these drugs include monoclonal antibodies, chimeric molecules, and oral therapies. The use of hematopoietic stem cells will also be discussed and, in addition, we will look farther ahead at possible novel targets for the development of new immunomodulatory or neuroprotective pharmaceuticals.",
keywords = "Drugs, Investigational, Multiple sclerosis, Therapeutics",
author = "Harrison, {Daniel M.} and Peter Calabresi",
year = "2009",
month = "10",
day = "1",
doi = "10.4103/0972-2327.58279",
language = "English (US)",
volume = "12",
pages = "283--290",
journal = "Annals of Indian Academy of Neurology",
issn = "0972-2327",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "4",

}

TY - JOUR

T1 - Promising treatments of tomorrow for multiple sclerosis

AU - Harrison, Daniel M.

AU - Calabresi, Peter

PY - 2009/10/1

Y1 - 2009/10/1

N2 - The therapeutic options for multiple sclerosis are rapidly expanding. What was once seen as a disease with little hope for treatment is now a target of rapid drug development. Current therapies have demonstrated efficacy in limiting the impact of the disease, but none is fully effective in all patients. However, promising new treatments are on the horizon. In this review we will discuss potential novel immunomodulating drugs that are in advanced stages of investigation; these drugs include monoclonal antibodies, chimeric molecules, and oral therapies. The use of hematopoietic stem cells will also be discussed and, in addition, we will look farther ahead at possible novel targets for the development of new immunomodulatory or neuroprotective pharmaceuticals.

AB - The therapeutic options for multiple sclerosis are rapidly expanding. What was once seen as a disease with little hope for treatment is now a target of rapid drug development. Current therapies have demonstrated efficacy in limiting the impact of the disease, but none is fully effective in all patients. However, promising new treatments are on the horizon. In this review we will discuss potential novel immunomodulating drugs that are in advanced stages of investigation; these drugs include monoclonal antibodies, chimeric molecules, and oral therapies. The use of hematopoietic stem cells will also be discussed and, in addition, we will look farther ahead at possible novel targets for the development of new immunomodulatory or neuroprotective pharmaceuticals.

KW - Drugs

KW - Investigational

KW - Multiple sclerosis

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=72949100481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72949100481&partnerID=8YFLogxK

U2 - 10.4103/0972-2327.58279

DO - 10.4103/0972-2327.58279

M3 - Article

C2 - 20182576

AN - SCOPUS:72949100481

VL - 12

SP - 283

EP - 290

JO - Annals of Indian Academy of Neurology

JF - Annals of Indian Academy of Neurology

SN - 0972-2327

IS - 4

ER -